Alligator Bioscience AB
- Biotech or pharma, therapeutic R&D
Alligator Bioscience is developing antibody-based, tumor-directed cancer immunotherapies. Alligator has three clinical stage mono- and bispecific antibodies in development and novel bispecific platforms available for collaboration. Lead asset, mitazalimab, is a phase 3 ready, best-in-class CD40 agonist.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}